[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368372-105":59,"doc-detail-368372-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","oncogenic-and-immunological-roles-of-frs2-and-its-potential-value-in-retroperitoneal-liposarcoma-from-bioinformatics-analysis-to-clinicopathological-evidence","Oncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma - from Bioinformatics Analysis to Clinicopathological Evidence","","Retroperitoneal liposarcoma (RLPS) is a rare malignancy with limited options beyond surgery, making novel therapeutic targets and prognostic biomarkers essential. This study explores fibroblast growth factor receptor substrate 2 (FRS2), positioned near MDM2 on chromosome 12q13-15, for its biological function and clinical relevance. Bioinformatics across public databases evaluates differential FRS2 expression and its associations with sarcoma outcomes. Immunohistochemistry in 82 RLPS cases links FRS2 levels to tumor progression and survival.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncogenic-and-immunological-roles-of-frs2-and-its-potential-value-in-retroperitoneal-liposarcoma-from-bioinformatics-analysis-to-clinicopathological-evidence/368372/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncogenic-and-immunological-roles-of-frs2-and-its-potential-value-in-retroperitoneal-liposarcoma-from-bioinformatics-analysis-to-clinicopathological-evidence/368372.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is identifying new targets for retroperitoneal liposarcoma important?","Question",{"text":112,"@type":113},"RLPS lacks effective treatments beyond surgical intervention, and achieving complete resection is difficult, leading to local recurrence and poor outcomes. The study highlights the need for new therapeutic targets and prognostic biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were bioinformatics analyses used to assess FRS2 in cancers?",{"text":117,"@type":113},"Public databases (GTEx, TCGA, and cBioPortal) were used to examine differential FRS2 expression and extract clinicopathological features, prognostic outcomes, co-expressed genes, and immune-related metrics. GEPIA 2 assessed variation in FRS2 mRNA expression across cancer types.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical evidence from the RLPS cohort supports FRS2’s prognostic value?",{"text":121,"@type":113},"In 82 RLPS patients, FRS2 overexpression was observed in 58.53% of cases and correlated with age. Higher FRS2 expression was linked to poorer overall survival and disease-free survival, and multivariate analysis confirmed FRS2 as an independent prognostic factor.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368372,1792035348,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2025; 22(8): 1825-1836. doi: 10.7150/ijms.103802  \nResearch Paper  \nOncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma: from Bioinformatics Analysis to Clinicopathological Evidence  \nHao Yu1, Shuquan Li1, Yifan Wu1, Zhen Wang1, Xiaopeng Wang1, Sha Zhang2, Xiaoya Guan1, Bin Dong3, Chunyi Hao1􀀍, Xiuyun Tian1􀀍, Ang Lv1􀀍  \n1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.  \n2. Department of Critical Care Unit, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.  \n3. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Center Laboratory, Peking University Cancer Hospital & Institute, Beijing, China.  \n􀀍 Corresponding authors: Ang Lv, [leon1232121@126.com](leon1232121@126.com); Xiuyun Tian, [tianxiuyun@bjmu.edu.cn](tianxiuyun@bjmu.edu.cn); Chunyi Hao, [haochunyi@bjmu.edu.cn](haochunyi@bjmu.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.09.17; Accepted: 2025.02.11; Published: 2025.03.10  \nAbstract  \nBackground: Retroperitoneal liposarcoma (RLPS) is a rare malignancy with no effective treatment beyond surgical intervention. Identifying novel therapeutic targets and prognostic markers is critical to improving outcomes. Fibroblast growth factor receptor substrate 2 (FRS2), located near MDM2 on chromosome 12q13-15, has a biological role and prognostic value in liposarcoma, which remain to be fully explored.  \nMethods: Bioinformatics tools were used to analyze the differential expression of FRS2 across various malignancies using public databases, such as GTEx, TCGA, and cBioPortal. In sarcomas (SARC), clinicopathological features, prognostic outcomes, co-expressed genes, levels of tumor-infiltrating immune cells, immunostimulators, major histocompatibility complex (MHC) molecules, and immunochemokines were extracted from multiple public databases. Tumor specimens from 82 RLPS patients at our sarcoma center were collected, and FRS2 expression was assessed through immunohistochemistry.  \nResults: FRS2 was found to be upregulated and amplified in most cancers. GEPIA 2 analysis showed significant variation in FRS2 mRNA expression across cancer types, especially in sarcomas (SARC). Lower FRS2 expression in SARC was correlated with improved overall survival (OS) and disease-free survival (DFS). FRS2 may affect the tumor immune microenvironment, inhibiting immune cell infiltration and promoting immune evasion. In our RLPS cohort, FRS2 overexpression was observed in 58.53%(48/82) of cases and was correlated with age (P = 0.009). High FRS2 expression was associated with poorer OS and DFS (P = 0.049 and P \u003C 0.001, respectively), and multivariate analysis confirmed FRS2 as an independent prognostic factor.  \nConclusion: FRS2 may serve as a potential prognostic biomarker and therapeutic oncogene target. Additionally, FRS2 could play a role in immune cell infiltration in SARC and represents a promising immunotherapeutic target for cancer treatment.  \nKeywords: FRS2, retroperitoneal liposarcoma, therapeutic target, immunotherapy, prognosis, survival analysis  \nIntroduction  \nLiposarcoma (LPS) is a malignant mesenchymal tumor that constitutes approximately 15-20% of all soft tissue sarcomas (STS) and is one of the most common STS subtypes [1-2] . LPS is categorized into  \nfive subtypes: well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid/round cell liposarcoma (MLPS), pleom","cbCaigABKKVtM635","https://ap.wps.com/l/cbCaigABKKVtM635","pdf",6324106,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Disease background and clinical need\n## Genetic context and rationale for FRS2\n# Study aims and design","[{\"question\":\"Why is identifying new targets for retroperitoneal liposarcoma important?\",\"answer\":\"RLPS lacks effective treatments beyond surgical intervention, and achieving complete resection is difficult, leading to local recurrence and poor outcomes. The study highlights the need for new therapeutic targets and prognostic biomarkers.\"},{\"question\":\"How were bioinformatics analyses used to assess FRS2 in cancers?\",\"answer\":\"Public databases (GTEx, TCGA, and cBioPortal) were used to examine differential FRS2 expression and extract clinicopathological features, prognostic outcomes, co-expressed genes, and immune-related metrics. GEPIA 2 assessed variation in FRS2 mRNA expression across cancer types.\"},{\"question\":\"What clinical evidence from the RLPS cohort supports FRS2’s prognostic value?\",\"answer\":\"In 82 RLPS patients, FRS2 overexpression was observed in 58.53% of cases and correlated with age. Higher FRS2 expression was linked to poorer overall survival and disease-free survival, and multivariate analysis confirmed FRS2 as an independent prognostic factor.\"}]","Oncogenic and Immunological Roles of FRS2 and its Potential Value in Retroperitoneal Liposarcoma - from Bioinformatics Analysis to Clinicopathological Evidence | PDF",1790176581,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df20d0647dee0ce00fe25d32196fb779.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/776c2618d050234920c7f3d9097d4418.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e19dfaa59e91d775f9eb45f9a7c2cf8e.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4838e9dc6c43c7a68bc6a306da9be137.webp",980,1268]